Baudax Bio, Inc.

OTCPK:BXRX.Q Stock Report

Market Cap: US$52.0

Baudax Bio Management

Management criteria checks 2/4

Baudax Bio's CEO is Gerri Henwood, appointed in Nov 2019, has a tenure of 5.08 years. directly owns 0.004% of the company’s shares, worth $0.00. The average tenure of the management team and the board of directors is 1.2 years and 5.1 years respectively.

Key information

Gerri Henwood

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.1yrs
CEO ownership0.004%
Management average tenure1.2yrs
Board average tenure5.1yrs

Recent management updates

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Recent updates

Baudax Bio stock down after pricing $6.2M equity offering

Aug 30

Baudax Bio to get US patent linked to pain drug Anjeso

Aug 22

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Aug 11

Cosette Pharmaceuticals appoints Rick Casten as CFO

Jul 06

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Sep 09

A First Look At Baudax Bio

May 30

Baudax Bio EPS misses by $0.08, misses on revenue

May 05

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

CEO Compensation Analysis

How has Gerri Henwood's remuneration changed compared to Baudax Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$663kUS$618k

-US$59m

Sep 30 2022n/an/a

US$13m

Jun 30 2022n/an/a

-US$67k

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$2mUS$618k

-US$20m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$38m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$603kUS$309k

-US$76m

Sep 30 2020n/an/a

-US$66m

Jun 30 2020n/an/a

-US$88m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$3mUS$46k

-US$33m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$51m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$2mUS$599k

-US$74m

Compensation vs Market: Insufficient data to establish whether Gerri's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Gerri's compensation has been consistent with company performance over the past year.

CEO

Gerri Henwood (72 yo)

5.1yrs

Tenure

US$663,224

Compensation

Dr. Geraldine A. Henwood, also known as Gerri, Ph D., has been the President, Chief Executive Officer and Director of Baudax Bio Inc. since 2019. She has been the Chief Development Officer of Iomab-B at Ac...

Leadership Team

NamePositionTenureCompensationOwnership
Geraldine Henwood
President5.1yrsUS$663.22k0.0037%
$ 0.002
Mike Choi
Vice President of Financial Planning & Analysisless than a yearno datano data
Natalie McAndrew
Consultant & Principle Accounting Officerless than a yearno datano data
Chan Kim Yong
Chief Scientific Officer & Director1.4yrsno datano data

1.2yrs

Average Tenure

53yo

Average Age

Experienced Management: BXRX.Q's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Geraldine Henwood
President5.1yrsUS$663.22k0.0037%
$ 0.002
Chan Kim Yong
Chief Scientific Officer & Director1.4yrsno datano data
Winston Churchill
Independent Director5.1yrsUS$95.11k0.0022%
$ 0.001
Wayne Weisman
Independent Chairman5.9yrsUS$113.59k0.0020%
$ 0.001
Andrew Drechsler
Independent Director4.3yrsUS$89.97k0.0020%
$ 0.001
William Ashton
Independent Director5.9yrsUS$99.97k0.0020%
$ 0.001
Arnold Baskies
Independent Director4.3yrsUS$82.47k0.0020%
$ 0.001

5.1yrs

Average Tenure

72yo

Average Age

Experienced Board: BXRX.Q's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 14:52
End of Day Share Price 2024/12/23 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Baudax Bio, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongJanney Montgomery Scott LLC
Jason ButlerJMP Securities
Gregory AurandNOBLE Capital Markets, Inc.